Macrolides and COVID-19: An optimum premise
Biomedical and Biotechnology Research Journal (BBRJ) · 2020
DOI: 10.4103/bbrj.bbrj_103_20 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical and Biotechnology Research Journal (BBRJ), 2020. Verfasst von HayderM Al-Kuraishy und 3 weiteren Autor:innen. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
The epidemic of coronavirus infection disease 19 (COVID-19), which started in Wuhan City, is caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) which binds angiotensin-converting enzyme 2 (ACE2) receptor, which is highly expressed by the lung epithelial cells. In COVID-19-induced acute respiratory distress syndrome, a hyperinflammatory syndrome with hypercytokinemia leads to acute lung injury and the development of respiratory failure. Macrolides are broad-spectrum, bacteriostatic antibiotics with significant anti-inflammatory and immunomodulatory effects. Different preclinical and clinical studies have shown that macrolides inhibit cytokine release, attenuate the inflammatory response, and improve immunoglobulin response. Azithromycin potentiates the anti-SARS-CoV-2 activity of chloroquine in COVID-19. However, azithromycin alone is effective initially in the management of COVID-19 due to its antiviral and anti-inflammatory activity. The antiviral potential of azithromycin is linked to different mechanisms, including modulation of lysosomal activity and the interaction points between SARS-CoV-2 and ACE2 receptor. Therefore, macrolides, chiefly azithromycin, are an effective drug against COVID-19 through direct antiviral effect or via the modulation of hyperinflammatory status.
Zitieren
APA
Al-Kuraishy, H., Al-Naimi, M., Lungnier, C., & Al-Gareeb, A. (2020). Macrolides and COVID-19: An optimum premise. Biomedical and Biotechnology Research Journal (BBRJ). https://doi.org/10.4103/bbrj.bbrj_103_20
Vancouver
Al-Kuraishy H, Al-Naimi M, Lungnier C, Al-Gareeb A. Macrolides and COVID-19: An optimum premise. Biomedical and Biotechnology Research Journal (BBRJ). 2020. doi:10.4103/bbrj.bbrj_103_20
BibTeX
@article{AlKuraishy2020,
author = {Al-Kuraishy, HayderM and Al-Naimi, MarwaS and Lungnier, ClaireM and Al-Gareeb, AliI},
title = {Macrolides and COVID-19: An optimum premise},
journal = {Biomedical and Biotechnology Research Journal (BBRJ)},
year = {2020},
doi = {10.4103/bbrj.bbrj_103_20}
}
EUVIMED